Methods of changing stool quality and/or frequency

FIELD: medicine, veterinary science.

SUBSTANCE: group of inventions concerns veterinary. A method for improving stool quality in animals consists in regulating the balance of metabolised cations and metabolised anions consumed by an animal in good supply for improving stool quality. A method of changing stool frequency in the animal includes regulating the balance of metabolised cations and metabolised anions consumed by the animal in good supply for changing stool frequency. The composition for changing stool quality and/or frequency in animals contains at least one component chosen from the group including metabolised cations, and at least one component chosen from the group including metabolised anions where the balance of metabolised cations and metabolised anions is regulated by an amount changing stool quality and/or frequency in animals.

EFFECT: group of inventions allows maintaining normal functioning of intestines in animals.

22 cl, 1 tbl, 1 ex

 

Cross-reference to related applications

This application claims priority of the provisional application U.S. serial No. 60/741632, filed December 2, 2005, the description of which is included as references.

The LEVEL of TECHNOLOGY

The scope of the invention

This invention relates primarily to methods changes in the quality and/or stool frequency in animals and, in particular, to methods changes in the quality and/or stool frequency in animals by regulating the balance metabolisable cations to metabolisable the anions consumed by the animal.

Description of the prior art,

The quality and frequency of stools, mainly determined by five factors: the digestibility of food components, the level of fibers, health status, activity level and water consumption. When these factors are balanced, the chair is primarily designed, solid, dark color and has no strongly pronounced odor. The chair, with these properties, is considered as the chair of good quality. If these factors are not balanced, chair, mainly soft, unformed, watery, light in colour and has a very distinct smell. The chair, with these properties, especially the weak, watery stools, is regarded as the chair of poor quality.

The poor quality of the chair and his irregular frequency can be call the Ana to various factors, for example, abnormal intestinal motility, increases intestinal permeability, presence is not absorbed osmoticheski active substances in the intestine or substances that cause diarrhea. Similarly some fodder for animals, especially known in the prior art as a rich food can cause bad quality of the chair. Often the animal, using such feeds have problems with a chair, such as irregular bowel movements or retching physiological functions at the wrong time. These physiological urge to shipments, mainly expressed in frequent weak and watery stool. In some cases, data failures with chair are classified as diarrhea.

Ways of regulating the quality and frequency of stools, focused on the use of Antidiarrhoeal drugs and compounds that improve the quality of the chair. For example, in US 6280779 discussed with feed containing chemically modified starches and gums, useful for maintaining the normal functioning of the intestines and promote acceptable quality chair. W0050632711 discusses the use of herbal mixtures for the treatment of gastrointestinal disorders, affecting the quality of the chair. US 5919760 discusses the use of octreotide for the treatment of diarrhoea, and W096259401 discloses the use of mixtures containing carrots, rice, bananas, and g is uCoz to treat diarrhea. Although these methods are suitable, however, there is a need for new methods and mixtures for change and, thereby, improve the quality and frequency of stool.

The invention

Thus, the purpose of this invention is to provide methods for improving the quality of the chair of the animal.

Another purpose of this invention is the provision of means for changing the frequency of the chair of the animal.

Another purpose of this invention is the provision of products in kit form suitable for changes and improvements in the quality and/or stool frequency.

These and other goals and objectives are achieved by adjusting the balance (ratio) metabolisable cations and metabolisable anions consumed by the animal in sufficient quantity to change and accordingly improve the quality and/or stool frequency of the animal. Kits comprising combinations of cations, anions, feed, connection, instructions for use and accessories useful to change the quality and/or stool frequency, are also available.

Additional objectives, features and advantages of this invention will be obvious to specialists in this field who will examine this patent.

Detailed description of the invention

In one aspect of the present image is eenie represents how changes in the quality of the chair of the animal. On the other hand, this invention is a means for changing the frequency of the chair of the animal. These methods include the regulation of the balance metabolisable cations to metabolisable the anions consumed by the animal in sufficient amount to change the quality and/or stool frequency of the animal.

The term "animal" means any animal that is susceptible to or suffering from the chair of poor quality and/or has irregular stool frequency. The animal is a suspect in the disease or condition, if the animal has symptoms that indicate that the animal develops a painful condition or disease. The animal, "suffering from the disease or condition, if the animal has symptoms that indicate that the animal has already developed this condition or disease.

These methods are useful for a variety of humanoid and nechelovekopodobnoe animals, including birds, animals from squad bovine, canine, equine, feline, goat, rat, sheep, and pig-like, and are particularly useful for use in animals from groups a dog and cat, including the usual dogs and cats. In some embodiments, the animal is a member of the squad Carvinora (carnivorous). In some embodiments, is an animal of the dog squad and in other embodiments is an animal from the squad feline is. In some embodiments is an animal companion. A companion can be, for example, a pet of any kind, which contains as a pet.

An animal companion can also be an animal of various common domesticated species such as dogs (Canis familaris) and cats (Felis domesticus), regardless of whether the animal is only as Pets. Thus, animal companion, include, for example, dogs, cats, contained for control of rodents, as well as cats and dogs kept only as Pets.

These cations and anions useful in this invention can be any of the cations or anions suitable for use in animals. In one embodiment of metabolisable cations are selected from the group consisting of calcium, sodium, potassium and magnesium and metabolisable anions are selected from the group consisting of phosphorus, chloride and sulfur.

Balance metabolisable cations to metabolisable the anions can be determined by any method known to skilled specialists. For example, one method for measuring balance metabolisable cations to metabolisable the anions is a cumulative count

cation-anion balance of the diet of the animal (DCAB), which is determined by counting sovokupnogo the amount of sodium, potassium, calcium and magnesium, regularly consumed by the animal, and minus the total amount of chloride, sulfur and phosphorus, regularly consumed by the animal. Cm. Baker et al., relative food for dogs and cats, Ann.Rev.Nutr. 11:239-63(1991).

In regulating the balance of metabolisable cations and metabolisable anions consumed by the animal, mainly, it was found that the increase of the balance of metabolisable cations to metabolisable the anions leads to the consolidation of the chair and to reduce the frequency of stools. Conversely, a decrease balance metabolisable cations to metabolisable the anions will lead to the indulgence of the chair and the increase in stool frequency.

In some embodiments, when an animal is suspected problem or already suffering from weak and/or frequent stools, quality and frequency of stools can be improved by increasing the balance of metabolisable cations to metabolisable the anions, which makes it possible to seal the chair of the animal and reducing its frequency. In some embodiments, the balance of the cations to the anions can be increased by increasing the total amount of calcium, sodium, potassium and magnesium, regularly consumed by the animal, total phosphorus, chloride, and sulfur, regularly consumed by the animal. For example, the balance of metabolisable cations to metabolisable the anions can be increased is by increasing the intake of animal at least one mixture, including the excess of the cations of calcium, sodium, potassium or magnesium. The balance can be increased by lowering the intake of animal at least one mixture comprising an excess of anions consisting of chloride, phosphorus or sulfur.

In other embodiments, when the animal is susceptible to or already suffering from constipation, quality and/or stool frequency can be improved by lowering the balance metabolisable cations to metabolisable the anions consumed by the animal, making it possible for some relief and increased stool frequency. In some embodiments, the balance of the cations to the anions can be reduced by reducing the total amount of calcium, sodium, potassium and magnesium, regularly consumed by the animal, relative to the total amount of phosphorus, chloride and sulfur, regularly consumed by the animal. For example, the balance of metabolisable cations to metabolisable the anions can be reduced by reducing the intake of animal at least one composition comprising an excess of cations of calcium, sodium, potassium or magnesium. The balance can be reduced by reducing the intake of animal at least one composition consisting of a surplus of anions consisting of chloride, phosphorus or sulfur.

In some embodiments, the balance metabolisable cations to metabolisable the anions consumed by the animal, can be adjusted by Koh is Melania animal composition, including a certain number of one or more metabolisable cations or metabolisable anions, altering the quality of the chair. Such compositions may include a feed composition containing one or more ingredients suitable for consumption by animals. In some embodiments the feed ingredients of the composition include dry food (i.e. food, containing from about 3 to 11% water). In some embodiments, the ingredients of the feed mixture include half wet food (i.e. food that contains from about 25 to 35% water). In some embodiments the feed composition includes wet food (i.e. food that contains from about 60 to more than approximately 87% water). In some embodiments the feed composition includes refreshments, snacks, food additive or partially or completely edible toy.

In some embodiments, the balance metabolisable cations to metabolisable the anions consumed by the animal, can be adjusted by assigning one or more Antidiarrhoeal components and substances against constipation. The term "anti-diarrhoeal component" means any compound, composition, or drug useful for preventing or treating diarrhea. The term "remedy against constipation" means a compound, composition, or drug useful for preventing the disgust or the treatment of constipation.

In some embodiments, the balance metabolisable cations to metabolisable the anions consumed by the animal, can be adjusted by assigning one or more compositions, including myself substances that improve the gastro-intestinal tract, selected from the group consisting of probiotics and prebiotics. Probiotics are live microorganisms that have a healing effect, mainly in the prevention and treatment of specific conditions in medicine, when there is pushelement food. It is assumed that probiotics have a positive impact on biological outcomes by the phenomenon known as anti-settling. Probiotics promote the process by which natural anaerobic flora reduces the concentration of potentially harmful (mainly aerobic) bacteria in the digestive tract. More moderate action of probiotics, such as supply of enzymes or increased activity of enzymes in the digestive tract may be important and to improve other functions of the body, which is also attributed to probiotics.

Prebiotics are an integral part of food difficult to digest, which mainly affect the health of the host, selectively stimulating the growth and/or activity of bacteria in the colon. Prebiotic-fructooligo the saccharide (FOS) found in nature in many foods, such as wheat, onions, bananas, honey, garlic, leeks. FOS can be extracted from chicory root or synthesized enzymatically from sucrose. The FOS fermentation in the large intestine leads to the emergence of a large number of physiological effects, including increasing the number of bifidobacteria in the colon, increasing calcium absorption, increased fecal volume, by reducing transit time through the GI tract, it is also possible lowering of blood lipids. The allowable increase in the level of bifidobacteria has a positive effect on health by increasing complex compounds that capture potentially dangerous pathogenic viruses and bacteria by lowering the level of ammonia in the blood, through the production of vitamins and enzymes that promote digestion. Useful life of probiotic bacteria such as lactobacilli and bifidobacteria, attach great importance, as they have a positive effect on the immune system by improving the microbial balance in the gut, which leads to an increased formation of antibodies and increased phagocytic (absorbing or consuming) activity of white blood cells. Bifidobacteria laktis can be an effective probiotic Supplement to food to improve the quality of some aspects of cleto the aqueous immunity in the elderly.

The increase in the consumption of probiotics improves the condition of the cells throughout the body, they can be a useful additive to improve natural cell-mediated immunity in healthy people. Probiotics include many types of bacteria, but mostly they were selected from four major types of bacteria: lactobacillus acidophilus, Bifidobacterium, Lactobacillus, and pediococcus. The amount of probiotics and prebiotics, appointed by the animal, is determined by a qualified specialist in this field and depends on the type and the basic properties of probiotics and prebiotics and species and natural condition of the patient, including age, gender, overall health, the extent of microbial depletion of the organism, the presence of harmful bacteria and diet of the animal. Mainly, probiotics are assigned to the animal in amounts of from one to twenty billion working per day to maintain a healthy intestinal microflora, preferably from five billion to approximately ten billion live bacteria per day. Mainly, probiotics administered in sufficient quantity to positively promote healthy microflora in the digestive tract and cause an increase in the number of "good" bacteria. The typical amount of from about one to ten grams at one time or from about five to forty percent of R is comencemos consumption of animal fibers in the day.

In another aspect, the present invention represents the sets that are used to change the quality and/or stool frequency, which include a certain amount, altering the quality and frequency of stools, changing the amount of at least one metabolisable cation or metabolisable anion. In some embodiments, the kit further includes one or more Antidiarrhoeal substances or substances against constipation and one or more tools that enhance the gastrointestinal tract selected from the group consisting of probiotics and prebiotics. In some embodiments, the kit further includes instructions for at least one of: (1) feeding the animal with the purpose to adjust the balance of metabolisable cations and metabolisable anions consumed by the animal, or (2) the introduction of anti-diarrhoeal remedies, or remedies of constipation, or tools, which improves the functioning of the gastrointestinal tract in combination with a mixture of regulating the quality and frequency of stool.

In some embodiments, the set is placed in separate containers in a single package or placed in separate containers in the actual package corresponding to this component set to change the quality and/or stool frequency, changing the amount of at least one ingredient comprising metabolisable cation or IU analiziruemykh anion, and at least (1) one of the ingredients, including a variety of metabolisable cation or metabolisable anion; (2) one or more ingredients for animal consumption; (3) one or more agents that enhance the gastrointestinal tract selected from the group consisting of probiotics and prebiotics; (4) one or more anti-diarrhoeal agents; (5) one or more anti-constipation; (6) instructions for combining the one or more components of this kit for the preparation of compositions applicable for changes in the quality and/or frequency chair, and (7) instructions for using the one or more components of the set of governing the quality and/or stool frequency.

The term "one package"mainly means that the components in this kit are physically combined in one or more containers are treated as a unit for manufacture, distribution, sale or use. Containers include, but are not limited to, bags, boxes, bottles, compressed packaging wrap, fastened or fixed in another way components or combinations of these components. One package, for example, can be containers or individual feed mixture, physically merged so that they are treated as a unit for manufacture, distribution, sale or use is litvania. The term "virtual package"mainly means that the components of the kit are mutually interconnected with instructions for applying one or more virtual components of the set, telling the consumer how to obtain components, i.e. a variant containing 1 component and instructions on how to enter the website as to come into contact with the recorded message, show a clear message as to come into contact with a specialist who gives instructions for the care and use of this set. When the kit includes a virtual package, the set is limited to the instructions of the virtual application in the particular circumstances, one or more components of the set.

In another aspect of the present invention predusmatrivaet the means for providing information or instructions to apply one or more of (1)using the balance metabolisable cations to metabolisable the anions consumed by the animal to change the quality and/or stool frequency, (2) mixing metabolisable cations and metabolisable anions with other components described in the present invention, (3) management of metabolisable cations and metabolisable anions animal, (4) using the kits of the present invention to change the quality and/or quantity of the chair, including a document, digital storage media of this information, the optical storage is s this information, audiopresenter or visual display containing the information or instructions for use. Preferably, the means for transmitting information were provided by the website or brochure, trade label, package insert, advertisement, or visual display containing the information or instructions for use. Useful information or instructions include, for example, (1) information and instructions for using the composition, method or kit described in this invention, and (2) information for contacts with a specialist who gives instructions and tips, if consumers have a question related to this invention and its use.

In an additional aspect, the present invention provides for a composition, which includes a number of at least one ingredient selected from the group consisting of metabolisable cations and metabolisable anions, for the manufacture of a medicine for the regulation of the quality of the chair. In another aspect the present invention provides use of a composition for the manufacture of medicines to regulate the quality or frequency of stools. Mainly, medicines are prepared by mixing the compounds or compositions with fillers, buffer substances, binders, plasticizers, dyes, solvents, sealing means, lubricating agents, fragrances, moisturizing remedies and other ingredients that are known to specialists in this field, in order to be useful for the manufacture of a medicinal product and manufacturing formulations of medicines, which is suitable for the reception of animals.

Examples

This invention may be further illustrated by the following example. However, it should be understood that this example is given merely for illustrative purposes and is not intended to limit the present invention.

Example 1

Seventy dogs were selected at random and divided into seven groups of ten dogs in the group. Each group received one of the seven feed containing the formula, different ratios of metabolisable cations and metabolisable anions. Balance metabolisable cations to metabolisable the anions was calculated according DCAB, as prescribed above, including the total amount of sodium, potassium, calcium and magnesium, minus the cumulative amount of chloride, sulfur and phosphorus. Dog eat feed for seven days, and during this period of time the chair of dogs were collected and evaluated. Each stool sample was ranked on a scale from one to five according to the water content, the weakness of the chair and ideality notion the chair.

Results showing the analysis of nutrients in each stern average rating of chair for each type of food and counting the number of chairs for a particular type of food, presented in table 1.

1,4
Table 1
Analysis of the compositions of nutrients in feed for dogsand
RoomFeed 1Feed 2Feed 3Food 4Feed 5Feed 6Food 7
Crude protein (%)20,218,619,122,1of 21.221,3a 21.5
Crude fat (%)13,014,014,29,813,814,012,8
Crude fiber (%)2,93,03,24,1the 4.73,7
Sodium (%)0,390,290,300,300,430,430,39
Potassium (%)0,870,640,710,631,291,551,52
Chloride (%)0,970,770,740,720,830,790,76
Sulfur (%)0,400,330,330,250,530,580,54
Calcium (%)0,630,670,660,750,66 0,620,66
Magnesium (%)0,060,050,050,160,090,110,11
Phosphorus (%)0,580,550,500,750,580,630,62
DCABb-107-81-23+4+21+30+62
The distribution of samples of feces scalewith4,04,14,34,34,64,84,6
The number of chairs for a certain periodd8485698068 6868
andCalculated on the basis of dry matter
bDCAB= (sodium+potassium+calcium+magnesium)-(chloride+sulphur+phosphorus)
withStool samples were ranked on a scale from 1 to 5, where 1 is weak watery stools, and 5 is the perfect chair.
dThe number of stools per seven-day period.

The results show that the balance of metabolisable cations to metabolisable the anions in the feed was directly related to the quality and frequency of stools. Dogs fed these feeds had an increased balance metabolisable cations to metabolisable the anions DCAB, showing the best estimate of the chair that serves as a sign of improvement in the quality of the chair, and reduced the number of stools, which is shown through a reduction in the frequency of stool.

In the description have been disclosed typical preferred embodiments of the present invention, and, although were utilized certain specific terms, these properties are used for General descriptions, transmitting the sense of this invention, in General, and not to limit. It is obvious that many variations and modifications of the present invention are possible in light of the above information. And therefore, it should be understood that the invention may be implemented differently than described certain specific is systematic manner.

The terms "include," "includes" and "including" should be interpreted as a rather inclusive than exclusive.

If not specified differently, all technical and scientific terms, and any acronyms used in this paper have the same value, which should be understood as the well-known ordinary skills in the scope of this invention. Despite the fact that any of the compositions, methods, kits and tools for information transfer, similar or equivalent to those described in this work can be used for carrying out the invention, preferred compositions, methods, kits and tools for information transfer described in this work.

All links above are included in the description in the scope in which the reference is permitted by law. Discussion these links mainly intended to draw conclusions on the basis of estimates made by the authors. The non-recognition of any of these links (or any links) is relevant to the prior art. The applicants of the present invention reserves the right to challenge the accuracy and appropriateness of any of these links.

1. The way to improve the quality of the chair in animals, including the regulation of the balance metabolisable cations to metabolisable the anions consumed by the animal in quite the number to improve the quality of the chair.

2. The method according to claim 1, in which metabolisable cations selected from the group consisting of calcium, sodium, potassium, magnesium.

3. The method according to claim 1, in which metabolisable anions selected from the group consisting of phosphorus, chloride and sulfur.

4. The method according to claim 1, in which the quality of the chair is improved by increasing the balance of metabolisable cations to metabolisable the anions.

5. The method according to claim 4, in which the balance is increased by increasing the aggregate amount of calcium, sodium, potassium and magnesium, regularly consumed by the animal, relative to the total amount of phosphorus, chloride and sulfur, regularly consumed by the animal.

6. The method according to claim 4, in which the balance is increased by increasing the intake of animal food, at least one composition comprising cationic excess calcium, sodium, potassium, magnesium.

7. The method according to claim 4, in which the balance is increased by reducing the consumption of animal in writing, at least one composition comprising anionic excess phosphorus, chloride or sulfur.

8. The method according to claim 1, further including placing the animal at least one compound selected from the group consisting of one or more tools, which improve the condition of the gastrointestinal tract, and one or more anti-diarrhoeal agents.

9. The method according to claim 1, in which the quality of the chair is improved by reducing b is lance metabolisable cations to metabolisable the anions.

10. The method according to claim 9, in which the balance is reduced by reducing the total amount of calcium, sodium, potassium or magnesium, regularly consumed by the animal, relative to the total amount of phosphorus, chloride and sulfur, regularly consumed by the animal.

11. The method according to claim 9, in which the balance is reduced by reducing the intake of animal food, at least one composition comprising cationic excess calcium, sodium, potassium or magnesium.

12. The method according to claim 9, in which the balance is reduced by increasing the intake of animal food, at least one composition comprising anionic excess phosphorus, chloride or sulfur.

13. The method according to claim 9, further including placing the animal at least one compound selected from the group consisting of one or more tools, which improve the condition of the gastrointestinal tract, and one or more anti-constipation.

14. The way that modifies the frequency of the chair of the animal, including the regulation of the balance metabolisable cations to metabolisable the anions consumed by the animal in sufficient quantity to change the frequency of the chair.

15. The method according to 14, in which metabolisable cation selected from the group consisting of calcium, sodium, potassium or magnesium.

16. The method according to 14, in which metabolisable anion selected from the group consisting of phosphorus, chloride sludge is sulfur.

17. The method according to 14, in which the stool frequency is reduced by increasing the balance of metabolisable cations to metabolisable the anions.

18. The method according to 14, in which the frequency of bowel movements increased by reducing the balance of metabolisable cations to metabolisable the anions.

19. The method according to 14, further including placing the animal at least one compound selected from the group consisting of one or more tools, which improve the condition of the gastrointestinal tract, Antidiarrhoeal and means against constipation.

20. Set, suitable for changes in the quality of the chair in animals, comprising in separate containers in a single package or in separate containers in a virtual package, the corresponding component set, the number of at least one metabolisable cation or metabolisable anion, altering the quality of the chair as defined in claim 1, and at least one (1) ingredient, including a variety of metabolisable cation or metabolisable anion, (2) one or more ingredients of feed composition for animals, (3) one or more means of improving the condition of the gastrointestinal tract, selected from the group consisting of probiotics and prebiotics, (4) one or more anti-diarrhoeal funds, (5) one or more anti-constipation, (6) statement p is a combination of one or more components, related to this set, for the preparation of compositions suitable for changes in the quality of the chair, and (7) instructions for using the one or more components of the set to change the quality of the chair.

21. Set, suitable for changes in stool frequency in animals, comprising in separate containers in a single package or in separate containers in a virtual package, the corresponding component set, the number of at least one metabolisable cation or metabolisable anion, changing the frequency of the chair, as defined in 14, and at least one (1) ingredient, including a variety of metabolisable cation or metabolisable anion, (2) one or more ingredients of feed composition for animals, (3) one or more means of improving the condition of the gastrointestinal tract, selected from the group consisting of probiotics and prebiotics, (4) one or more anti-diarrhoeal funds, (5) one or more anti-constipation, (6) how the combination of one or more components related to this set, for the preparation of compositions suitable for changes in stool frequency, and (7) instructions for using the one or more components of the set to change in stool frequency.

22. Composition for changes in the quality of the chair and/or stool frequency in animals, including, hence, is her least one ingredient selected from the group consisting of metabolisable cations, and at least one ingredient selected from the group consisting of metabolisable anions, where the balance of metabolisable cations to metabolisable the anions adjusted number that changes as the chair and/or stool frequency in animals.



 

Same patents:

FIELD: veterinary.

SUBSTANCE: preparation of treatment of gastrointestinal diseases in newborn calves, includes zeolite, tetracycline, sodium acetate and flour of dried leather bergenia rhizome (Bergenia crassifolia), at the following ratio of components, wt %: Zeolite 44.5-48.5; Sodium acetate 44.5-48.5; Flour from dried rhizome of leather bergenia (Bergenia crassifolia) 4.2-8.2; Tetracycline 1.0-2.0. Preparation is fed in dose of 35 g per head 2 times per day until recovery.

EFFECT: therapeutic efficiency makes 100%.

1 tbl, 4 ex

FIELD: medicine; veterinary science.

SUBSTANCE: cerebrolysin dosed 1 ml once a day within 3-4 days is injected intramuscularly to an affected animal.

EFFECT: high effectiveness.

1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine and represents pharmacologic composition for diarrhea treatment in case of irritate bowels syndrome in women, which contains from 0.002 to 0.02 mg of ramosetron hydrochloride as daily dose or equivalent molar amount of ramosetron or its other pharmacologically acceptable salt as active ingredient.

EFFECT: invention ensures more efficient treatment of diarrhea syndrome in case of irritate bowels syndrome in women.

6 cl, 10 ex

FIELD: medicine; veterinary medicine.

SUBSTANCE: medical product contains polyvinylpyrolidone, Furacilinum, glucose, Acidum ascorbinicum and sodium hypochlorite at the certain component proportion.

EFFECT: reduction of diarrhea duration on 36% (to 2.8 days); calf safety at level of 95% and additional weight increase on 15-44% after treatment, reduction of medical products consumption.

2 tbl, 2 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention concerns a combination for proliferative disease treatment which contains antidiarrheal agent and epothylon derivative of formula (1) or epothylon derivative, method of diarrhoeia management, associated with epothylon introduction of formula (1), pharmaceutical composition, trade packing and medical product, including antidiarrheal agent and epothylon derivative.

EFFECT: compositions have improved efficiency.

9 cl, 6 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to antagonists of adenosine A2B receptors and their using in treatment of mammals in different pathological states, such as digestive, immunological, neurological disorders and cardiovascular diseases caused both hyper-proliferation of cells and their apoptosis and similar disorders. Also, invention relates to methods for synthesis of these compounds and pharmaceutical composition containing thereof. The aim of the present invention is use of compounds of the general formulae (I) and (II) for preparing pharmaceutical composition possessing antagonistic activity with respect to adenosine A2B receptors wherein radical values are given in the invention description.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

41 cl, 12 sch, 35 ex

FIELD: medicine.

SUBSTANCE: means has 0.001-0.05 mg of Ramozetron Hydrochloride as daily dose or equivalent molar quantity of Ramozetron or its other pharmaceutically permissible salt as active ingredient.

EFFECT: enhanced effectiveness of treatment.

12 cl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to pharmaceutical compositions with anti-diarrheic effect. Pharmaceutical composition comprises the therapeutically effective amount of loperamide hydrochloride as an active component and special additives. Lactose, starch, aerosil, talk and stearate are used as special additives. Pharmaceutical composition is prepared in the form of solid gelatinous capsules. Loperamide capsules satisfy all requirement of the State Pharmacopoeia of XI Edition. Invention provides bioavailability of the pharmaceutical composition of loperamide capsules at the level 98.5%.

EFFECT: improved and valuable pharmaceutical properties of composition.

3 cl, 1 tbl, 3 ex

FIELD: veterinary science.

SUBSTANCE: the suggested preparation for treating diarrhea in farm animals youngsters contains bismuth salt in the form of bismuth-potassium ammonium citrate and, additionally, polyethylenoxide, moreover, preferably, it contains 1.5-2.5%-polyethylenoxide solution and 1.5-2.5%-bismuth-potassium ammonium citrate solution. The method for treating diarrhea deals with introducing the above-mentioned preparation once or twice daily for 1-2 d at the dosage of 1-75 ml/kg body weight. In young foxes it should be introduced at the dosage of 60-75 ml/kg body weight, in calves - at the dosage of 1-3 ml/kg body weight, in lambs - at the dosage of 2-3 ml/kg body weight. Application of the present complex preparation and therapeutic method enables to shorten terms of therapy by 1.5-2 times, decreases expenses for therapy by 3-5 times and provides decreased toxicological impact the preparation upon animal body.

EFFECT: higher efficiency of therapy.

6 cl, 3 ex, 2 tbl

The invention relates to pharmaceutical

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to urology, and concerns conservative treatment of bladder leukoplakia (squamous metaplasia). That is ensured by intrabladder instillations of a solution containing as follows: heparin - 25 thousands, 2% lidocaine - 2 ml, 0.9% saline solution - 13 ml. Instillations are applied 2-3 times a week.

EFFECT: owing to local effect of said solution, the method provides restoration of a destroyed mucopolysaccharide layer, rapid normalisation of a clinical-morphological presentation of the disease, prolonged recurrence-free period without by-effects.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to regenerative medicine, physiotherapy, reflexotherapy. The method involves daily extremely high frequencies puncture by extremely high frequencies electromagnetic radiation in a noise mode at frequency 59-63 GHz. There are involves acupuncture points (AP): E 36 (2), T 14, T 20, GI 4(2), TR 2(2), GI 11(2), RP 6(2), C 7(2), MC 6(2). In addition, the acupuncture points: C 9(2); VB 10(2), T 13, MC 3(2), MC 4(2), GI 10(2), RP 4(2), MC 5(2), C 8(2) are exposed. The exposure is carried out within 10-13 o'clock. Thus on the first day, the points E 36(2), T14, T 20, GI 4(2), TR 2 (2), C 9(2) are covered. On the second day, the exposure involves VB 10(2), T 13, GI 11(2), MC 3(2). On the third day, there are exposed C 7(2), MC 6(2), RP 6(2), MC 4(2). On the fourth day, GI 10(2), RP 4(2), MC 6(2) are exposed. On the fifth day, MC 5(2), C 7(2), RP 6(2), C 8(2) are exposed, for the next days said exposure is performed once again. One hour after the session, oxygen cocktail is introduced.

EFFECT: method improves clinical effectiveness, increases remission length due to combined application of extremely high frequencies puncture and oxygen doses; it is simple, and has no by-effects.

3 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gastroenterology, and concerns treatments of the patients with hyperbilirubinemia. That is ensured by conventional pharmacotherapy combined with oral introduction of hepabene in a dose 1 capsule 3 times a day at mealtimes from the first day of treatment. From the next day, intravenous introductions of ozonised physiologic saline of table salt in volume 200 ml with ozone concentration 500 mcg/ml and introduction rate 8-10 ml/min is applied. The course includes 6 infusions every second day. After that preparation Hepabene is continued in a dose 1 capsule twice a day at mealtimes during 7-10 days.

EFFECT: method provides effective decrease in bilirubin with reduced treatment time.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gastroenterology, and concerns treatments of the patients with hyperbilirubinemia. That is ensured by conventional pharmacotherapy combined with oral introduction of hepabene in a dose 1 capsule 3 times a day at mealtimes from the first day of treatment. From the next day, intravenous introductions of ozonised physiologic saline of table salt in volume 200 ml with ozone concentration 500 mcg/ml and introduction rate 8-10 ml/min is applied. The course includes 6 infusions every second day. After that preparation Hepabene is continued in a dose 1 capsule twice a day at mealtimes during 7-10 days.

EFFECT: method provides effective decrease in bilirubin with reduced treatment time.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to preparing solutions containing silver ions and can be used in manufacturing of high-effective preparations for medicine and veterinary science. The method for preparing ion silver solution consists in using distilled water of resistance within 0.1 to 18 MOhm to be poured in a chemically pure dish and heated up on water-bath to temperature more than 60°C within 30 minutes, a DC joined-up silver ioniser cartridge is immersed in water. After electric conduction is observed, the solution is stirred while the ionisation cycles repeated some times at a standstill and in stirring to ensure the required concentration of the ion silver solution. The silver ioniser cartridge represents an electrochemical cell with silver electrodes. Preparation and preservation of the ion silver solution is carried out in the dark and in an air-free medium.

EFFECT: invention allows preparing high concentrated and high pure drug with low toxicity and allergenic capacity, and reliable reproducibility of physical and chemical characteristics.

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention concerns a multi-purpose biomaterial. The biomaterial contains KH2PO4, metal oxide (namely, MgO), calcium-containing compound, sugar and water. Typical calcium-containing compounds include, but not limited, tricalcium phosphate.

EFFECT: biomaterial exhibits an excellent adhesive properties and also unexpected and essential osteoproliferative possibilities and is used as a bone graft, bulking agent, adhesive, binding agent, fastener and cement and can be easily introduced with a syringe.

26 cl, 1 dwg, 5 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention concerns a multi-purpose biomaterial. The biomaterial contains KH2PO4, metal oxide (namely, MgO), calcium-containing compound, sugar and water. Typical calcium-containing compounds include, but not limited, tricalcium phosphate.

EFFECT: biomaterial exhibits an excellent adhesive properties and also unexpected and essential osteoproliferative possibilities and is used as a bone graft, bulking agent, adhesive, binding agent, fastener and cement and can be easily introduced with a syringe.

26 cl, 1 dwg, 5 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention concerns a multi-purpose biomaterial. The biomaterial contains KH2PO4, metal oxide (namely, MgO), calcium-containing compound, sugar and water. Typical calcium-containing compounds include, but not limited, tricalcium phosphate.

EFFECT: biomaterial exhibits an excellent adhesive properties and also unexpected and essential osteoproliferative possibilities and is used as a bone graft, bulking agent, adhesive, binding agent, fastener and cement and can be easily introduced with a syringe.

26 cl, 1 dwg, 5 tbl, 3 ex

FIELD: medicine, veterinary science.

SUBSTANCE: method of improving a cartilage involving condition and reducing the related defects in an animal, including; introduction to said animal of effective amount of sulphur amino acid which makes at least 1.2 wt % and effective amount of manganese which makes at least 50 p/mln and higher of dry weight. The method for prevention of cartilage degradation in the animal includes feeding of said animal with a composition including sulphur amino acid and manganese. A composition for improving the cartilage involving condition and reducing the related defects in the animal, containing: effective amount of sulphur amino acids which makes at least 1.2 wt % and effective amount of manganese which makes at least 50 p/mln and higher of dry weight.

EFFECT: invention provides reduction of the visually observed cartilage defects.

22 cl, 6 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine notably to the field of surgery and may be used for general peritonitis treatment. For it abdominal cavity is irrigated with ozonised physiological solution of sodium chloride with concentration 20 mcg /ml and then is drained. Then in right and left hypochondriums and right and left iliac regions drainage tubes with ultrasonic sources are installed. Then ultrasonic vibration is measured in the middle level of abdominal cavity. If ultrasonic vibration is less than 500 kHz additional drainage tubes with ultrasonic sources are installed in right and left side channels of abdominal cavity. No more than 1 litter of the above mentioned ozonised physiological solution is infused in every drain tube daily. Besides continuous 500 kHz ultrasonic exposure is prescribed for the 1st-4th days and continuous 400 kHz ultrasonic exposure is prescribed for the 5th-7th days of therapy.

EFFECT: method provides the most effective abdominal cavity sanation thanks to steady and simultaneous abdominal cavity ultrasonic exposure in combination with bactericidal effect of ozonised solution in specified regime.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention concerns a composition obtained from a combination of vegetable oil or cod-liver oil with a compound which contains fatty acids analogues resistant to β-oxidation. The invention also concerns animals' fodder produced form a combination of vegetable oil and cod-liver oil containing fatty acids analogues resistant to β-oxidation, to application of the fodder with the purpose of improving the animal's body composition and to the product obtained from the above animals.

EFFECT: production of pharmaceutical or edible composition for prevention and/or treatment of insulin resistance, obesity, diabetes, fatty liver, hypercholesterinemia, dislipidemia, atherosclerosis, coronary heart disease, thrombosis, stenosis, myocardial infarction, apoplexy, hypertension, endothelial dysfunction, hypercoagulability, polycystic ovary syndrome, metabolic syndrome, malignant tumour, inflammatory disorder and poliferous skin lesions.

47 cl, 12 tbl, 2 ex, 4 dwg

Up!